Plerixafor
Plerixafor is a bicyclam CXCR4 chemokine receptor antagonist that blocks the interaction between CXCR4 and its ligand CXCL12/SDF-1, thereby mobilizing hematopoietic stem and progenitor cells from the bone marrow into the peripheral blood. It is used in combination with granulocyte colony-stimulating factor (G-CSF) to enhance stem cell mobilization prior to autologous stem cell transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
Molecular Weight
502.8000 g/mol
LogP
0.00
TPSA
78.70 Ų
Lipinski RO5
Fail
Therapeutic Areas
Mechanism of Action
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D Structure
Cite this structure
Embed this structure
SMILES
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1
InChI
InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
Molecular Formula
C28H54N8
HBD / HBA
6 / 8
Rotatable Bonds
4
Heavy Atoms
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Plerixafor is a bicyclam CXCR4 chemokine receptor antagonist that blocks the interaction between CXCR4 and its ligand CXCL12/SDF-1, thereby mobilizing hematopoietic stem and progenitor cells from the bone marrow into the peripheral blood. It is used in combination with granulocyte colony-stimulating factor (G-CSF) to enhance stem cell mobilization prior to autologous stem cell transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Plerixafor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL18442. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 65015. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="plerixafor"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/plerixafor/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/plerixafor/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/plerixafor/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="plerixafor"></drugfyi-drug>